Quanterix Corporation develops ultra-sensitive digital immunoassay platform and tools for life science research and diagnostics. The Company offers single molecule array (Simoa) platform, which uses single molecule measurements to detect protein biomarkers. The Company is also focusing to enable and develop novel therapies and diagnostics to facilitate in healthcare for earlier detection, monitoring, prognosis and, ultimately, prevention of disease. Simoa focuses on research and clinical testing applications and significantly advances enzyme-linked immunosorbent assay (ELISA) technology which is capable of unprecedented protein detection sensitivity. It also focuses on research and diagnostics for brain injuries, heart disease, cancer and other infectious diseases with its technology. The Company offers Simoa HD-1 analyzer, which is an automated immunoassay platform with multiplexing and custom assay capability.